Scarica l'app Stockscreener
1.62
5.19%
0.08
Dopo l'orario di chiusura:
1.54
-0.08
-4.94%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PYXS Giù?
Forum
Previsione
Precedente Chiudi:
$1.54
Aprire:
$1.56
Volume 24 ore:
441.40K
Relative Volume:
0.37
Capitalizzazione di mercato:
$97.52M
Reddito:
-
Utile/perdita netta:
$-73.79M
Rapporto P/E:
-0.8804
EPS:
-1.84
Flusso di cassa netto:
$-77.44M
1 W Prestazione:
-1.22%
1M Prestazione:
+3.85%
6M Prestazione:
-57.92%
1 anno Prestazione:
-59.80%
Intervallo 1D:
$1.56
$1.66
Intervallo di 1 settimana:
$1.5005
$1.67
Portata 52W:
$1.39
$6.85
Pyxis Oncology Inc Stock (PYXS) Company Profile
Nome
Pyxis Oncology Inc
Settore
Industria
Telefono
(617) 221-9059
Indirizzo
321 HARRISON AVENUE, BOSTON
Confronta PYXS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PYXS
Pyxis Oncology Inc
|
1.62 | 97.52M | 0 | -73.79M | -77.44M | -1.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 113.67B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 74.97B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.50B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 29.63B | 3.30B | -501.07M | 1.03B | -2.1146 |
Pyxis Oncology Inc Stock (PYXS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2024-11-08 | Iniziato | Stephens | Overweight |
| 2024-08-08 | Iniziato | Stifel | Buy |
| 2024-05-07 | Ripresa | Jefferies | Buy |
| 2024-02-09 | Iniziato | BTIG Research | Buy |
| 2024-01-23 | Iniziato | Leerink Partners | Outperform |
| 2023-09-05 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-11-02 | Iniziato | BofA Securities | Neutral |
| 2021-11-02 | Iniziato | Credit Suisse | Outperform |
| 2021-11-02 | Iniziato | Jefferies | Buy |
Mostra tutto
Pyxis Oncology Inc Borsa (PYXS) Ultime notizie
Pyxis Oncology plummets 38% on preliminary phase 1 data for cancer asset - MSN
Barclays PLC Purchases 46,997 Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World
Pyxis Oncology, Inc. (NASDAQ:PYXS) Holdings Raised by Jane Street Group LLC - Defense World
Pyxis Oncology stock hits 52-week low at $1.49 By Investing.com - Investing.com South Africa
Pyxis Oncology stock hits 52-week low at $1.49 - Investing.com India
Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives $9.43 Average Price Target from Analysts - MarketBeat
Pyxis Oncology, Inc. (NASDAQ:PYXS) Stock Position Raised by Geode Capital Management LLC - Defense World
Barclays PLC Increases Stock Position in Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World
State Street Corp Buys 208,344 Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World
Pick Pyxis in head and neck despite pullback on ADC phase I? - BioWorld Online
Pyxis Oncology stock outlook adjusted with focus on ADC program and cost management - Investing.com Nigeria
Pyxis Oncology stock outlook adjusted with focus on ADC program and cost management By Investing.com - Investing.com South Africa
Pyxis Oncology’s (PYXS) “Outperform” Rating Reiterated at Royal Bank of Canada - Defense World
Pyxis Oncology price target lowered to $8 from $10 at RBC Capital - Yahoo Finance
Pyxis Oncology shares target cut, outperform rating on pipeline update By Investing.com - Investing.com Australia
Pyxis Oncology shares target cut, outperform rating on pipeline update - Investing.com
Pyxis Oncology's (PYXS) Buy Rating Reiterated at HC Wainwright - MarketBeat
Pyxis Oncology's Deprioritizes Second Pipeline Asset, Analyst Applauds Move - Benzinga
Royal Bank of Canada Reaffirms Outperform Rating for Pyxis Oncology (NASDAQ:PYXS) - MarketBeat
Pyxis Oncology advances lead cancer drug PYX-201 By Investing.com - Investing.com Canada
Pyxis Oncology to Focus on PYX-201, Suspends PYX-106 Program - MarketWatch
Pyxis Oncology advances lead cancer drug PYX-201 - Investing.com
Pyxis Oncology to prioritize PYX-201, suspends investment in PYX-106 - TipRanks
Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201 - The Manila Times
Pyxis Oncology, Inc. Announces Portfolio Prioritization, Focusing Resources on Its Lead Clinical Program, PYX-201 - Marketscreener.com
Pyxis Oncology stock hits 52-week low at $1.5 amid market challenges - Investing.com Canada
Pyxis Oncology's SWOT analysis: ADC developer's stock shows promise amid trials - Investing.com Canada
Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives $10.00 Average Price Target from Brokerages - MarketBeat
Pyxis Oncology stock hits 52-week low at $1.64 - Investing.com
Pyxis Oncology stock hits 52-week low at $1.64 By Investing.com - Investing.com UK
Jacobs Levy Equity Management Inc. Makes New Investment in Pyxis Oncology, Inc. (NASDAQ:PYXS) - MarketBeat
14,897 Shares in Pyxis Oncology, Inc. (NASDAQ:PYXS) Bought by Intech Investment Management LLC - Defense World
Pyxis Oncology: Speculative Buy Opportunity With Multiple Catalysts Ahead (NASDAQ:PYXS) - Seeking Alpha
CFO & COO of Pyxis Oncology Pamela Connealy Buys 13% More Shares - Yahoo Finance
Pyxis Oncology CFO acquires shares worth $174,364 - Investing.com India
Pyxis Oncology CFO acquires shares worth $174,364 By Investing.com - Investing.com South Africa
Institutional owners may ignore Pyxis Oncology, Inc.'s (NASDAQ:PYXS) recent US$142m market cap decline as longer-term profits stay in the green - Yahoo Finance
Pressure on Pyxis despite promising PYX-201 data - The Pharma Letter
Pyxis Oncology's SWOT analysis: ADC innovator's stock poised for growth - Investing.com
Pyxis Oncology's SWOT analysis: ADC innovator's stock poised for growth By Investing.com - Investing.com UK
Pyxis Oncology Inc Azioni (PYXS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
5.49%
0.79%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):